수두-대상포진 바이러스 감염으로 입원한 소아에 대한 임상 고찰
Clinical Manifestations of Hospitalized Children Due to Varicella-Zoster Virus Infection
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
목적: 본 연구는 단일 기관에서 수두-대상포진 바이러스 감염으로 입원한 소아 환자의 임상 경과를 알아보고자 하였다. 방법: 2009년부터 2012년까지 서울대학교 어린이병원에서 피부 병변의 수포액으로 시행한 수두-대상포진 바이러스 배양검사와 중합효소 연쇄반응검사로 수두-대상포진 바이러스 감염증이 확진된 40명의 입원환자를 대상으로 하였다. 환자들의 의무기록을 통하여 진단 시 연령 및 성별, 수두 백신 시행유무, 임상증상 및 경과, 기저질환, 치료와 합병증에 대하여 분석하였다. 결과: 대상자 중 수두 환자는 16명, 대상포진 환자는 24명이었고, 연령 중앙값은 10.5세로 생후 16일부터 19세까지 분포하였다. 기저질환이 동반된 환자는 35명(87.5 %)이었고, 24명의 대상포진 환자 중 과거에 수두를 앓았던 경우가 11례에서 있었고, 재발한 대상포진은 1례에서 있었다. 20명(50%)은 이전에 수두 백신의 접종력이 있었고, 이 중 19명은 면역저하환자였다. 대부분의 환자(95 %)는 정맥용 또는 경구용 항바이러스제로 치료받았고, 정맥용 항바이러스제 투여 후 치료 실패는 관찰되지 않았다. 면역저하환자에서 발열의 기간은 평균 4.4일(1-10일)로 정상 면역력을 가진 환자와 비교하였을 때 유의한 차이는 없었으나, 항바이러스제의 투여기간은 평균 12일(7-23일)로 유의하게 길었다(P=0.014). 두 명(5.0%)의 환자에서 Streptococcus pyogenes와 Klebsiella oxytoca에 의한 이차 세균 감염이 확인되었으며, 1명(2.5%)에서 폐렴이, 11명(27.5%)에서 대상포진후 신경통이 합병되었다. 결론: 수두-대상포진 바이러스 감염은 면역저하 소아에서 발생할 시에 장기간의 항바이러스제 치료가 필요하므로 이 같은 환자들을 적극적으로 치료하고, 면밀하게 관찰하는 것이 필요하다.
Abstract
Purpose: This study was performed to describe the clinical manifestations of hospitalized children due to varicella-zoster virus (VZV) infection Methods: This study included 40 children who were hospitalized for varicella or herpes zoster at Seoul National University Children’s Hospital, 2009-2012. Diagnosis of VZV infection was confirmed by VZV PCR or culture from vesicular fluid. Medical records were reviewed to collect clinical features and outcome, antiviral treatment, history of varicella vaccination, and underlying diseases. Results: Sixteen patients with varicella and 24 patients with herpes zoster were included. Their median age was 10.5 years (16 days-19 years). Thirty-five (87.5%) patients had underlying diseases. Among 24 patients with herpes zoster, 11 patients had previous history of varicella and 1 had herpes zoster. Twenty patients (50%) had a history of varicella vaccination, and 19 immunocompromised patients had VZV infection despite of vaccination. Most (95%) patients were treated by intravenous or oral acyclovir, and no treatment failure of intravenous acyclovir was found. The median duration of fever was 4.4 days (1-10 days), and that of antiviral treatment was 12 days (7-23 days) in immunocompromised patients. Immunocompromised patients received longer duration of antiviral treatment than imunocompetent patients (P=0.014). Eleven (27.5 %) immunocompromised patients had postherpetic neuralgia, 2 (5%) had proven co-infection by Streptococcus pyogenes and Klebsiella oxytoca, and 1 (2.5%) complicated with pneumonia. Conclusion: Immunocompromised children require longer duration of treatment and are at risk of severe complication associated with VZV infection. Early initiation of antiviral therapy and close monitoring are necessary for those in immunocpompromised conditions.
참고문헌 (31)
- Davison AJ, "The complete DNA sequence of varicella-zoster virus", J Gen Virol, 67(Pt 9), pp.1759~1816 (1986)
- Schmidt-Chanasit J, "Evolution and worldwide distribution of varicella-zoster virus clades", Infect Genet Evol, 11, pp.1~10 (2011)
- Seward JF, "Varicella disease after introduction of varicella vaccine in the United States, 1995-2000", JAMA, 287, pp.606~611 (2002)
- Takahashi M, "Live vaccine used to prevent the spread of varicella in children in hospital", Lancet, 2, pp.1288~1290 (1974)
- Nguyen HQ, "Decline in mortality due to varicella after implementation of varicella vaccination in the United States", N Engl J Med, 352, pp.450~458 (2005)
- 오성희, "수두백신의 최신지견", Korean Journal of Pediatrics, 49(3), pp.229~234 (2006), 대한소아과학회
- 최은화, "수두 예방접종: 세계적인 현황과 우리나라 접종 스케줄에 대한 제안", Pediatric Infection and Vaccine, 15(1), pp.11~18 (2008), 대한소아감염학회
- 박수정, "소아？청소년 대상 포진 72예에 대한 임상적 고찰", 대한피부과학회지, 44(6), pp.664~668 (2006), 대한피부과학회
- 서필승, "청소년기 이후에 발생한 수두의 임상적 고찰", 대한피부과학회지, 43(7), pp.933~938 (2005), 대한피부과학회
- 이건홍, "성인기 수두 입원 환자의 임상적 특징에 대한 고찰", 대한피부과학회지, 48(4), pp.272~277 (2010), 대한피부과학회
- 박창근, "수두 예방접종의 시행여부에 따른 수두의 임상경과의 차이", 대한피부과학회지, 46(8), pp.1011~1019 (2008), 대한피부과학회
- Loparev VN, "DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine", J Infect Dis, 195, pp.502~510 (2007)
- Loparev VN, "Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping", J Virol, 78, pp.8349~8358 (2004)
- Carapetis JR, "The burden and cost of hospitalised varicella and zoster in Australian children", Vaccine, 23, pp.755~761 (2004)
- Marshall HS, "Changes in patterns of hospitalized children with varicella and of associated varicella genotypes following introduction of varicella vaccine in Australia", Pediatr Infect Dis J, 32, pp.530~537 (2013)
- van Lier A, "Hospitalization due to varicella in the Netherlands", BMC Infect Dis, 11, pp.85~ (2011)
- Kim SH, "Seroprevalence rate after one dose of varicella vaccine in infants", J Infect, 61, pp.66~72 (2010)
- Thomas SL, "What does epidemiology tell us about risk factors for herpes zoster?", Lancet Infect Dis, 4, pp.26~33 (2004)
- Nagasawa K, "High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis", Ann Rheum Dis, 49, pp.630~633 (1990)
- Morens DM, "An outbreak of varicella-zoster virus infection among cancer patients", Ann Intern Med, 93, pp.414~419 (1980)
- Adler AL, "An outbreak of varicella with likely breakthrough disease in a population of pediatric cancer patients", Infect Control Hosp Epidemiol, 29, pp.866~870 (2008)
- Folatre I, "Infections caused by varicella zoster virus in children with cancer aged less than 15 years old", Rev Med Chil, 131, pp.759~764 (2003)
- Arvin AM, "Antiviral therapy for varicella and herpes zoster", Semin Pediatr Infect Dis, 13, pp.12~21 (2002)
- Prober CG, "Acyclovir therapy of chickenpox in immunosuppressed children--a collaborative study", J Pediatr, 101, pp.622~625 (1982)
- Nyerges G, "Acyclovir prevents dissemination of varicella in immunocompromised children", J Infect Dis, 157, pp.309~313 (1988)
- Novelli VM, "Acyclovir administered perorally in immunocompromised children with varicella-zoster infections", J Infect Dis, 149, pp.478~ (1984)
- Meszner Z, "Oral acyclovir to prevent dissemination of varicella in immunocompromised children", J Infect, 26, pp.9~15 (1993)
- Jain Y, "Oral acyclovir in varicella zoster virus infections in children with acute lymphoblastic leukemia", Indian Pediatr, 37, pp.1239~1241 (2000)
- Carcao MD, "Sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocompromised children", Pediatr Infect Dis J, 17, pp.626~631 (1998)
- Bomgaars L, "Valacyclovir and acyclovir pharmacokinetics in immunocompromised children", Pediatr Blood Cancer, 51, pp.504~508 (2008)
- Eksborg S, "Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir?", Med Pediatr Oncol, 38, pp.240~246 (2002)